Gilead Sciences Inc (GILD) 76.89 $GILD
Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved
Arpita Dutt - Zacks Investment Research - Thu Sep 01, 9:54AM CDT
The overall healthcare sector was under pressure with focus going back to the pricing policies of pharma and biotech companies.
GILD: 76.89 (-0.53), ALXN: 123.67 (-1.96), MYL: 39.97 (-1.95), AMGN: 169.77 (-0.36), ARIA: 10.12 (-0.07), RIGL: 3.40 (-0.05), REGN: 388.64 (-4.76)
Gilead Sciences, Palo Alto Networks, The Mosaic Company, Alibaba, and The Kroger Co and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Wed Aug 31, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BABA, GILD, KR, MOS, and PANW.
KR: 32.50 (+0.54), GILD: 76.89 (-0.53), MOS: 29.49 (+0.32), PANW: 145.18 (+4.52), BABA: 99.25 (+1.83)
Watch for Gilead Sciences to Potentially Rebound After Falling 1.77% Yesterday
Comtex SmarTrend(R) - Mon Aug 29, 11:45AM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $77.63 to a high of $79.70. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $79.27 on volume of 10.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 76.89 (-0.53)
Gilead Sciences Set to Possibly Rebound After Yesterday's Selloff of 1.77%
Comtex SmarTrend(R) - Mon Aug 29, 11:44AM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $77.63 to a high of $79.70. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $79.27 on volume of 10.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 76.89 (-0.53)
Gilead Sciences Inc. Stock Is Now Poised To Make A Comeback
Jack Foley - Amigobulls - Mon Aug 29, 2:39AM CDT
The Gilead Sciences Inc. (NASDAQ:GILD) stock has taken a huge beating this year. Here's why it's poised to make a comeback.
GILD: 76.89 (-0.53)
Global Pulmonary Arterial Hypertension Market to Grow 4.95% by 2021 - Key Players are Bayer AG, Gilead Sciences & Pfizer - Research and Markets
BusinessWire - Fri Aug 26, 10:26AM CDT
Research and Markets has announced the addition of the "Global Pulmonary Arterial Hypertension (PAH) Market (By Drug Class, By Region, By Country): Opportunities and Forecasts (2016-2021)" report to their offering.
GILD: 76.89 (-0.53)
Gilead Sciences Stock A Buy On Compelling Valuations
Arie Goren - Amigobulls - Fri Aug 26, 3:55AM CDT
The depressed valuations and a huge product pipeline make Gilead Sciences, Inc. (NASDAQ:GILD) an attractive buy at the current price levels.
GILD: 76.89 (-0.53)
Stock Market News for August 25, 2016
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 8:55AM CDT
Benchmarks ended in the red on Wednesday following decline in Mylan’s shares, which had a negative impact on the biotech stocks and eventually on the broader healthcare sector
FIT: 14.96 (+0.01), ENDP: 19.82 (-0.41), VRTX: 95.11 (+0.36), GILD: 76.89 (-0.53), CEO: 123.29 (+2.65), MYL: 39.97 (-1.95), ILMN: 167.90 (-0.66), SDRL: 2.42 (+0.09), HPQ: 14.49 (-0.01), PVH: 108.56 (+0.38)
Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 1:09PM CDT
Acquisitions are back in focus in the biotech sector with Medivation (MDVN) agreeing to be acquired by Pfizer for $14 billion.
MDVN: 80.85 (-0.08), BIIB: 313.59 (+7.56), PTLA: 21.03 (+0.17), CLVS: 23.40 (-0.19), GILD: 76.89 (-0.53), ALXN: 123.67 (-1.96), REGN: 388.64 (-4.76)
John Snow, Inc. (JSI) to Manage Grants for the Dreams-Innovation Challenge
PR Newswire - Wed Aug 24, 9:12AM CDT
John Snow, Inc. (JSI) has been selected as funds manager for the DREAMS Innovation Challenge (DREAMS-IC).JSI will oversee awards dedicated to reducing new HIV infections among adolescent girls and young women by 40 percent in the high-burden geographic areas of 10 African countries by the end of 2017, under a public-private partnership between PEPFAR, the Bill & Melinda Gates Foundation, Girl Effect, Johnson & Johnson, Gilead Sciences, and Viiv Healthcare.
JNJ: 119.32 (+0.24), GILD: 76.89 (-0.53)
Watch for Shares of Gilead Sciences (GILD) to Approach Resistance at $81.95
Comtex SmarTrend(R) - Tue Aug 23, 9:22AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $81.02 today and have reached the first resistance level of $81.44. Should the shares continue to rise, the resistance pivots of $81.95 and $82.88 will be of interest.
GILD: 76.89 (-0.53)
Gilead (GILD) Truvada Gets EU Approval for Label Expansion
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 9:02AM CDT
Gilead Sciences (GILD) once-daily Truvada gains EU approval for reducing the risk of sexually acquired HIV-1 infection.
GILD: 76.89 (-0.53), GERN: 2.75 (+0.02), CORT: 5.31 (-0.04), ANIK: 47.89 (-0.05)
Galapagos (GLPG) Advances RA Drug Filgotinib to Phase III
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:43AM CDT
Galapagos (GLPG) announced the initiation of a phase III program on filgotinib for the treatment of patients with rheumatoid arthritis.
GILD: 76.89 (-0.53), ANIP: 59.86 (-1.56), GLPG: 54.35 (-0.05)
Kelly A. Kramer Joins Gilead Sciences' Board of Directors
BusinessWire - Tue Aug 23, 7:55AM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) announced today that Kelly A. Kramer has been appointed to the company's Board of Directors and Audit Committee.
GILD: 76.89 (-0.53), CSCO: 31.83 (+0.25)
ETFs in Focus on Pfizer's Medivation Acquisition
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 11:01AM CDT
The pharma giant, Pfizer (PFE) announced to acquire Medivation (MDVN) for $14 billion.
IHE: 147.95 (-0.83), MDVN: 80.85 (-0.08), GILD: 76.89 (-0.53), MRK: 62.98 (+0.08), PFE: 34.77 (+0.09), FHLC: 34.54 (+0.03), SNY: 39.18 (+0.77), VHT: 133.16 (+0.19), XLV: 72.65 (+0.08), CELG: 105.49 (-0.88)
Is Gilead Sciences Stock A Buy After The Recent Correction?
Sangara Narayanan - Amigobulls - Fri Aug 19, 5:03AM CDT
Gilead is currently suffering from investor apprehension about Harvoni. With a huge pipeline in place, is this kind of stock price hammering justified?
GILD: 76.89 (-0.53)
Biotech Stock Roundup: Vertex Slips on Study Halt, Aurinia Plunges on Lupus Data
Arpita Dutt - Zacks Investment Research - Wed Aug 17, 2:49PM CDT
With second quarter earnings season drawing to a close, focus in back on pipeline and regulatory updates.
BIIB: 313.59 (+7.56), VRTX: 95.11 (+0.36), AUPH: 2.05 (+0.10), OGXI: 0.53 (-0.02), GILD: 76.89 (-0.53), AVEO: 0.90 (-0.01), AMGN: 169.77 (-0.36)
BetterInvesting Top 100 Grew 13.3 Percent Annually for 5 Years Through July
PR Newswire - Wed Aug 17, 1:26PM CDT
At the end of July, the BetterInvesting Top 100 Index (BIXX), reflecting the portfolios of Main Street investors, gained 13.3 percent annually for the previous five years, versus annual growth of 13.6 percent for the Standard & Poor's 500 Equal-Weight Index (based on a total return for both indexes in which dividends are reinvested).
AMZN: 772.44 (+1.82), V: 82.00 (+0.70), SWKS: 74.62 (-0.47), GILD: 76.89 (-0.53), FB: 126.51 (+0.34), AL: 29.31 (unch), WFC: 50.55 (+0.12), GNTX: 17.86 (+0.13), AAPL: 107.73 (+1.00), LUV: 36.89 (+0.30)
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 1.36%
Comtex SmarTrend(R) - Wed Aug 17, 12:02PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $79.30 to a high of $80.52. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $80.09 on volume of 4.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 76.89 (-0.53)
Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved
Arpita Dutt - Zacks Investment Research - Thu Sep 01, 9:54AM CDT
The overall healthcare sector was under pressure with focus going back to the pricing policies of pharma and biotech companies.
GILD: 76.89 (-0.53), ALXN: 123.67 (-1.96), MYL: 39.97 (-1.95), AMGN: 169.77 (-0.36), ARIA: 10.12 (-0.07), RIGL: 3.40 (-0.05), REGN: 388.64 (-4.76)
Gilead Sciences, Palo Alto Networks, The Mosaic Company, Alibaba, and The Kroger Co and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Wed Aug 31, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BABA, GILD, KR, MOS, and PANW.
KR: 32.50 (+0.54), GILD: 76.89 (-0.53), MOS: 29.49 (+0.32), PANW: 145.18 (+4.52), BABA: 99.25 (+1.83)
Watch for Gilead Sciences to Potentially Rebound After Falling 1.77% Yesterday
Comtex SmarTrend(R) - Mon Aug 29, 11:45AM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $77.63 to a high of $79.70. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $79.27 on volume of 10.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 76.89 (-0.53)
Gilead Sciences Set to Possibly Rebound After Yesterday's Selloff of 1.77%
Comtex SmarTrend(R) - Mon Aug 29, 11:44AM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $77.63 to a high of $79.70. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $79.27 on volume of 10.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 76.89 (-0.53)
Gilead Sciences Inc. Stock Is Now Poised To Make A Comeback
Jack Foley - Amigobulls - Mon Aug 29, 2:39AM CDT
The Gilead Sciences Inc. (NASDAQ:GILD) stock has taken a huge beating this year. Here's why it's poised to make a comeback.
GILD: 76.89 (-0.53)
Global Pulmonary Arterial Hypertension Market to Grow 4.95% by 2021 - Key Players are Bayer AG, Gilead Sciences & Pfizer - Research and Markets
BusinessWire - Fri Aug 26, 10:26AM CDT
Research and Markets has announced the addition of the "Global Pulmonary Arterial Hypertension (PAH) Market (By Drug Class, By Region, By Country): Opportunities and Forecasts (2016-2021)" report to their offering.
GILD: 76.89 (-0.53)
Gilead Sciences Stock A Buy On Compelling Valuations
Arie Goren - Amigobulls - Fri Aug 26, 3:55AM CDT
The depressed valuations and a huge product pipeline make Gilead Sciences, Inc. (NASDAQ:GILD) an attractive buy at the current price levels.
GILD: 76.89 (-0.53)
Stock Market News for August 25, 2016
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 8:55AM CDT
Benchmarks ended in the red on Wednesday following decline in Mylan’s shares, which had a negative impact on the biotech stocks and eventually on the broader healthcare sector
FIT: 14.96 (+0.01), ENDP: 19.82 (-0.41), VRTX: 95.11 (+0.36), GILD: 76.89 (-0.53), CEO: 123.29 (+2.65), MYL: 39.97 (-1.95), ILMN: 167.90 (-0.66), SDRL: 2.42 (+0.09), HPQ: 14.49 (-0.01), PVH: 108.56 (+0.38)
Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 1:09PM CDT
Acquisitions are back in focus in the biotech sector with Medivation (MDVN) agreeing to be acquired by Pfizer for $14 billion.
MDVN: 80.85 (-0.08), BIIB: 313.59 (+7.56), PTLA: 21.03 (+0.17), CLVS: 23.40 (-0.19), GILD: 76.89 (-0.53), ALXN: 123.67 (-1.96), REGN: 388.64 (-4.76)
John Snow, Inc. (JSI) to Manage Grants for the Dreams-Innovation Challenge
PR Newswire - Wed Aug 24, 9:12AM CDT
John Snow, Inc. (JSI) has been selected as funds manager for the DREAMS Innovation Challenge (DREAMS-IC).JSI will oversee awards dedicated to reducing new HIV infections among adolescent girls and young women by 40 percent in the high-burden geographic areas of 10 African countries by the end of 2017, under a public-private partnership between PEPFAR, the Bill & Melinda Gates Foundation, Girl Effect, Johnson & Johnson, Gilead Sciences, and Viiv Healthcare.
JNJ: 119.32 (+0.24), GILD: 76.89 (-0.53)
Watch for Shares of Gilead Sciences (GILD) to Approach Resistance at $81.95
Comtex SmarTrend(R) - Tue Aug 23, 9:22AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $81.02 today and have reached the first resistance level of $81.44. Should the shares continue to rise, the resistance pivots of $81.95 and $82.88 will be of interest.
GILD: 76.89 (-0.53)
Gilead (GILD) Truvada Gets EU Approval for Label Expansion
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 9:02AM CDT
Gilead Sciences (GILD) once-daily Truvada gains EU approval for reducing the risk of sexually acquired HIV-1 infection.
GILD: 76.89 (-0.53), GERN: 2.75 (+0.02), CORT: 5.31 (-0.04), ANIK: 47.89 (-0.05)
Galapagos (GLPG) Advances RA Drug Filgotinib to Phase III
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:43AM CDT
Galapagos (GLPG) announced the initiation of a phase III program on filgotinib for the treatment of patients with rheumatoid arthritis.
GILD: 76.89 (-0.53), ANIP: 59.86 (-1.56), GLPG: 54.35 (-0.05)
Kelly A. Kramer Joins Gilead Sciences' Board of Directors
BusinessWire - Tue Aug 23, 7:55AM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) announced today that Kelly A. Kramer has been appointed to the company's Board of Directors and Audit Committee.
GILD: 76.89 (-0.53), CSCO: 31.83 (+0.25)
ETFs in Focus on Pfizer's Medivation Acquisition
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 11:01AM CDT
The pharma giant, Pfizer (PFE) announced to acquire Medivation (MDVN) for $14 billion.
IHE: 147.95 (-0.83), MDVN: 80.85 (-0.08), GILD: 76.89 (-0.53), MRK: 62.98 (+0.08), PFE: 34.77 (+0.09), FHLC: 34.54 (+0.03), SNY: 39.18 (+0.77), VHT: 133.16 (+0.19), XLV: 72.65 (+0.08), CELG: 105.49 (-0.88)
Is Gilead Sciences Stock A Buy After The Recent Correction?
Sangara Narayanan - Amigobulls - Fri Aug 19, 5:03AM CDT
Gilead is currently suffering from investor apprehension about Harvoni. With a huge pipeline in place, is this kind of stock price hammering justified?
GILD: 76.89 (-0.53)
Biotech Stock Roundup: Vertex Slips on Study Halt, Aurinia Plunges on Lupus Data
Arpita Dutt - Zacks Investment Research - Wed Aug 17, 2:49PM CDT
With second quarter earnings season drawing to a close, focus in back on pipeline and regulatory updates.
BIIB: 313.59 (+7.56), VRTX: 95.11 (+0.36), AUPH: 2.05 (+0.10), OGXI: 0.53 (-0.02), GILD: 76.89 (-0.53), AVEO: 0.90 (-0.01), AMGN: 169.77 (-0.36)
BetterInvesting Top 100 Grew 13.3 Percent Annually for 5 Years Through July
PR Newswire - Wed Aug 17, 1:26PM CDT
At the end of July, the BetterInvesting Top 100 Index (BIXX), reflecting the portfolios of Main Street investors, gained 13.3 percent annually for the previous five years, versus annual growth of 13.6 percent for the Standard & Poor's 500 Equal-Weight Index (based on a total return for both indexes in which dividends are reinvested).
AMZN: 772.44 (+1.82), V: 82.00 (+0.70), SWKS: 74.62 (-0.47), GILD: 76.89 (-0.53), FB: 126.51 (+0.34), AL: 29.31 (unch), WFC: 50.55 (+0.12), GNTX: 17.86 (+0.13), AAPL: 107.73 (+1.00), LUV: 36.89 (+0.30)
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 1.36%
Comtex SmarTrend(R) - Wed Aug 17, 12:02PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $79.30 to a high of $80.52. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $80.09 on volume of 4.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 76.89 (-0.53)
